Compare IQIYI Inc - ADR (IQ) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Repligen Corporation Common Stock — how do they compare? IQIYI Inc - ADR trades at $0.94 (market cap $918.03M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 12.3× IQIYI Inc - ADR's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Repligen Corporation Common Stock for 0 Days on average.
| IQ | RGEN | |
|---|---|---|
Market Cap | $918.03M | $11.31B |
Volume | 10,354,180 | 1,216,919 |
Sector | Media | Health |
52-Week High | $2.35 | $194.57 |
52-Week Low | $0.86 | $102.87 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $2.41B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $0.99, down 2.78% today, with a neutral technical signal. The company reported a net loss of $206 million in 2025 despite beating EPS estimates in recent quarters. Revenue has declined from $31.9B in 2023 to $27.3B in 2025. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights AI-driven content initiatives, including the successful 'The Ferry Man' series.
The outlook is cautious; while AI innovation offers growth potential, persistent revenue declines and negative margins pose risks. The stock's low P/S and P/B ratios suggest undervaluation, but profitability challenges and high debt levels require careful monitoring. Upside depends on successful execution of AI content strategy and return to revenue growth.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
